摘要
目的了解陕西省耐多药肺结核病患者发现及纳入治疗情况,探索符合当地情况的耐多药防治策略。方法从中国疾病预防控制中心结核病管理信息系统数据库中获得2015—2019年陕西省登记的耐药信息。采用描述性流行病学方法进行分析。计数资料采用例数、率或构成比表示。组间率的比较用χ^2检验,以P<0.05为差异有统计学意义。结果2015—2019年陕西省耐多药患者总筛查率为52.99%,新病原学阳性患者筛查率为51.57%,高危人群患者耐多药筛查率为62.25%,均从2017年开始呈逐年升高趋势(趋势χ^2=4462.291,P<0.001;趋势χ^2=4288.520,P<0.001;趋势χ^2=297.085,P<0.001);耐多药结核病患者检出率为8.39%,检出率最高的是复发患者(22.96%);耐多药肺结核患者纳入治疗率为72.73%,总纳入治疗率及新病原学阳性患者纳入治疗率呈逐年下降趋势(趋势χ^2=8.788,P=0.003;趋势χ^2=12.806,P<0.001)。结论陕西省耐多药患者筛查率、检出率、纳入治疗率均不高。需采取针对性措施,加强对耐多药肺结核患者的防控和治疗。
Objective To understand the detection and treatment inclusion of multidrug resistant tuberculosis(MDR TB)patients in Shaanxi province,and explore the MDR TB prevention and treatment strategies.Methods Drug resistance information registered in Shaanxi from 2015 to 2019 were collected from the tuberculosis management information system of Chinese Center for Disease Control and Prevention.Descriptive epidemiological methods were used for the analysis.Enumeration data were expressed by case number,rate or constituent ratio.The intergroup rate was compared byχ^2 test,and P<0.05 was considered to be statistically significant.Results In Shaanxi,the screening rate of MDR TB patients was52.99%,the screening rate of multidrug resistance in new etiologic positive patients was 51.57%,and the screening rate of multidrug resistance in population at high risk was 62.25%.All the three rates began to show increasing trends year by year in2017(trendχ^2=4462.291,P<0.001,trendχ^2=4288.520,P<0.001,trendχ^2=297.085,P<0.001).The detection rate of MDR TB patients was 8.39%.The multidrug resistance detection rate was highest in patients with TB recurrence(22.96%).The treatment inclusion rate of MDR TB patients was 72.73%.The total treatment inclusion rate of MDR TB patients and the treatment inclusion rate of new etiologic positive patients showed downward trends year by year(trendχ^2=8.788,P=0.003;trendχ^2=12.806,P<0.001).Conclusion The screening rate,detection rate and treatment inclusion rate of MDR TB patients were not high in Shaanxi.It is necessary to further improve the prevention,control and treatment of MDR TB.
作者
赵燕
张天华
孙小璐
郑骁
Zhao Yan;Zhang Tianhua;Sun Xiaolu;Zheng Xiao(Shaanxi Provincial Institute for Tuberculosis Control and Prevention,Xi′an 710048,Shaanxi,China)
出处
《疾病监测》
CAS
2020年第9期823-826,共4页
Disease Surveillance
基金
陕西省卫生计生科研基金(No.2016D097)。
关键词
耐多药
肺结核
筛查
治疗
Multidrug resistant
Tuberculosis
Screening
Treatment
